Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents

Zydus Cadila receives final approval from USFDA for Droxidopa capsules

It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.

Zydus completes enrolment for two Phase Ill trials of Desidustat

The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business

Zydus eyes $6 bn market with strong COVID-19 portfolio

With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

FDA nod to first-ever treatment for fatal pediatric Menkes disease

FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission

If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease

FDA issues CRL for Sentynl’s copper histidinate for treatment of Menkes disease

IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President